EPHA1 and breast carcinoma: Preclinical testing of possible combination therapies will also benefit from study of these mouse models to determine the effects of Eph expression and targeting on sensitisation to established therapies, as seen with trastuzumab resistance associated with EphA2 in HER2-positive breast cancer.